Valneva Spotlights Chikungunya Vaccine Progress at World Vaccine Congress
Event summary
- Valneva to present chikungunya vaccine updates at the 26th World Vaccine Congress in Washington DC from March 31 to April 2, 2026.
- Susanne Eder-Lingelbach to discuss Phase IV and real-world evidence studies for IXCHIQ® on April 1, 2026.
- Dr. Juan Carlos Jaramillo to participate in a panel on mosquito-borne vaccines alongside CEPI and Kenyan health officials.
- Valneva’s IXCHIQ® vaccine pilot campaign in Brazil has vaccinated over 12,000 people to date.
- Company to engage with current and potential partners at booth #538 during the event.
The big picture
Valneva’s participation in the World Vaccine Congress underscores the growing urgency around mosquito-borne diseases, particularly as climate change exacerbates their spread. The company’s focus on chikungunya aligns with global health priorities, as highlighted by the WHO, and positions Valneva as a key player in addressing unmet medical needs in infectious disease prevention. The strategic partnerships and real-world data presented at the event could accelerate IXCHIQ®’s commercialization and influence future vaccine development efforts.
What we're watching
- Regulatory Progress
- How the real-world evidence from Brazil’s pilot campaign will influence IXCHIQ®’s regulatory approvals and market expansion.
- Partnership Dynamics
- Whether Valneva can leverage the World Vaccine Congress to secure new collaborations for its chikungunya and other vaccine candidates.
- Market Adoption
- The pace at which IXCHIQ® gains traction in regions with high chikungunya prevalence, particularly as climate change expands mosquito habitats.
Related topics